Results 341 to 350 of about 229,722 (383)

Xanthines and Phosphodiesterase Inhibitors.

Handbook of Experimental Pharmacology, 2017
D. Spina, Clive P. Page
semanticscholar   +1 more source

A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction

Journal of Cardiovascular Pharmacology and Therapeutics, 2018
R. Kloner, P. Goggin, I. Goldstein, G. Hackett, M. Kirby, I. Osterloh, J. Parker, R. Sadovsky   +7 more
semanticscholar   +1 more source

Phosphodiesterase 7A

2007
Valeria Vasta, Joseph A. Beavo
openaire   +1 more source

Phosphodiesterases

2008
Jennifer L. Glick, Joseph A. Beavo
openaire   +2 more sources

PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.

Journal of Medicinal Chemistry, 2016
Chimed Jansen, A. Kooistra, Georgi K. Kanev, R. Leurs, I. D. de Esch, C. de Graaf   +5 more
semanticscholar   +1 more source

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

Nature Medicine, 2005
E. Takimoto, H. Champion, Manxiang Li, Diego Belardi, Shuxun Ren, E. Rodriguez, D. Bedja, K. Gabrielson, Yibin Wang, D. Kass   +9 more
semanticscholar   +1 more source

Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

Pharmacology and Therapeutics, 2006
C. Lugnier
semanticscholar   +1 more source

Phosphodiesterase DosP increases persistence by reducing cAMP which reduces the signal indole

Biotechnology and Bioengineering, 2015
Brian W. Kwan, D. Osbourne, Ying Hu, M. Benedik, T. Wood   +4 more
semanticscholar   +1 more source

Phosphodiesterase

Shikha Kaushik, Sarvesh Paliwal, Neeraj Masand, Vaishali Manikrao Patil   +3 more
openaire   +2 more sources

Phosphodiesterase 1A, calmodulin dependent

AfCS-Nature Molecule Pages, 2009
Anuraag Shrivastav, Ponniah Selvakumar, Jerry Wang, Rajendra Sharma   +3 more
openaire   +1 more source